IMMUNITYBIO, INC. Payments to Acquire Marketable Securities
IMMUNITYBIO, INC. (IBRX) reported Payments to Acquire Marketable Securities of $10.36 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-19.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2024-03-19
- IMMUNITYBIO, INC. payments to acquire marketable securities for the quarter ending 2023-03-31 was $158.00K, a 99.54% decline year-over-year.
- IMMUNITYBIO, INC. payments to acquire marketable securities for the quarter ending 2022-12-31 was $19.00K, a 99.99% decline year-over-year.
- IMMUNITYBIO, INC. payments to acquire marketable securities for the quarter ending 2022-09-30 was $86.00K, a 96.54% decline year-over-year.
- IMMUNITYBIO, INC. payments to acquire marketable securities for the quarter ending 2022-06-30 was $125.00K, a 28.57% decline year-over-year.
- IMMUNITYBIO, INC. payments to acquire marketable securities for fiscal 2023 was $10.36M, a 69.81% decline from fiscal 2022.
- IMMUNITYBIO, INC. payments to acquire marketable securities for fiscal 2022 was $34.31M, a 75.79% decline from fiscal 2021.
- IMMUNITYBIO, INC. payments to acquire marketable securities for fiscal 2021 was $141.75M, a 54.47% increase from fiscal 2020.
- IMMUNITYBIO, INC. payments to acquire marketable securities for fiscal 2020 was $91.77M, a 5.25% increase from fiscal 2019.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2023-12-31 | $10.36M 10-K · filed 2024-03-19 | |||
| 2023-03-31 | $158.00K 10-Q · filed 2023-05-11 | $177.00K derived: sum of 2 quarters · filed 2024-03-19 | $263.00K derived: sum of 3 quarters · filed 2024-03-19 | $388.00K derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $105.00K derived: sum of 2 quarters · filed 2024-03-19 | $230.00K derived: sum of 3 quarters · filed 2024-03-19 | $34.31M 10-K · filed 2024-03-19 |
| 2022-09-30 | $86.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $211.00K derived: sum of 2 quarters · filed 2022-11-09 | $34.29M 10-Q · filed 2022-11-09 | $173.29M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | $125.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $34.21M 10-Q · filed 2022-08-08 | $173.21M derived: sum of 3 quarters · filed 2024-03-19 | $175.69M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | $34.08M 10-Q · filed 2023-05-11 | $173.08M derived: sum of 2 quarters · filed 2024-03-19 | $175.57M derived: sum of 3 quarters · filed 2024-03-19 | $175.74M derived: sum of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | $139.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $141.48M derived: sum of 2 quarters · filed 2024-03-19 | $141.66M derived: sum of 3 quarters · filed 2024-03-19 | $141.75M 10-K · filed 2024-03-19 |
| 2021-09-30 | $2.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $2.66M derived: sum of 2 quarters · filed 2022-11-09 | $2.75M 10-Q · filed 2022-11-09 | $8.86M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $175.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $266.00K 10-Q · filed 2022-08-08 | $6.38M derived: sum of 3 quarters · filed 2023-03-01 | $77.20M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $91.00K 10-Q · filed 2022-05-10 | $6.21M derived: sum of 2 quarters · filed 2023-03-01 | $77.03M derived: sum of 3 quarters · filed 2023-03-01 | $81.56M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $6.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $76.94M derived: sum of 2 quarters · filed 2023-03-01 | $81.47M derived: sum of 3 quarters · filed 2023-03-01 | $91.77M 10-K · filed 2023-03-01 |
| 2020-09-30 | $70.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $75.35M derived: sum of 2 quarters · filed 2021-11-12 | $85.65M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $4.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $14.83M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $10.30M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | $87.19M 10-K · filed 2022-03-01 | |||
| 2018-03-31 | $32.04M 10-Q · filed 2018-05-07 | $68.28M derived: sum of 2 quarters · filed 2018-05-07 | $96.88M derived: sum of 3 quarters · filed 2018-05-07 | $118.19M derived: sum of 4 quarters · filed 2018-05-07 |
| 2017-12-31 | $36.24M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $64.84M derived: sum of 2 quarters · filed 2018-03-12 | $86.15M derived: sum of 3 quarters · filed 2018-03-12 | $111.36M 10-K · filed 2018-03-12 |
| 2017-09-30 | $28.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $49.91M derived: sum of 2 quarters · filed 2017-11-07 | $75.11M 10-Q · filed 2017-11-07 | $140.22M derived: sum of 4 quarters · filed 2018-05-07 |
| 2017-06-30 | $21.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $46.52M 10-Q · filed 2017-08-07 | $111.63M derived: sum of 3 quarters · filed 2018-05-07 | $153.68M derived: sum of 4 quarters · filed 2018-05-07 |
| 2017-03-31 | $25.21M 10-Q · filed 2018-05-07 | $90.31M derived: sum of 2 quarters · filed 2018-05-07 | $132.37M derived: sum of 3 quarters · filed 2018-05-07 | $186.81M derived: sum of 4 quarters · filed 2018-05-07 |
| 2016-12-31 | $65.11M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $107.16M derived: sum of 2 quarters · filed 2018-03-12 | $161.60M derived: sum of 3 quarters · filed 2018-03-12 | $273.00M 10-K · filed 2018-03-12 |
| 2016-09-30 | $42.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $96.49M derived: sum of 2 quarters · filed 2017-11-07 | $207.89M 10-Q · filed 2017-11-07 | $405.96M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-06-30 | $54.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $165.84M 10-Q · filed 2017-08-07 | $363.90M derived: sum of 3 quarters · filed 2018-03-12 | |
| 2016-03-31 | $111.40M 10-Q · filed 2017-05-08 | $309.46M derived: sum of 2 quarters · filed 2018-03-12 | ||
| 2015-12-31 | $198.07M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $198.07M 10-K · filed 2018-03-12 | ||
| 2015-09-30 | $0.00 10-Q · filed 2016-11-10 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |